Trial Profile
Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
- Indications Colorectal cancer; Liver metastases
- Focus Therapeutic Use
- Acronyms EXPERT
- 19 Jan 2019 Results (n=77) presented at the 2019 Gastrointestinal Cancers Symposium
- 09 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 23 May 2016 Results of a pooled analysis from EXPERT and EXPERT-C trials (n=269) published in the Annals of Oncology